Three-dimensional MR mapping of angiogenesis with α₅β₁(ανβ₃)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model
Our objectives were 1) to characterize angiogenesis in the MDA-MB-435 xenograft mouse model with three-dimensional (3D) MR molecular imaging using α₅β₁(RGD)- or irrelevant RGS-targeted paramagnetic nanoparticles and 2) to use MR molecular imaging to assess the antiangiogenic effectiveness of α₅β₁(αν...
Gespeichert in:
Veröffentlicht in: | The FASEB journal 2008-12, Vol.22 (12), p.4179-4189 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 4189 |
---|---|
container_issue | 12 |
container_start_page | 4179 |
container_title | The FASEB journal |
container_volume | 22 |
creator | Schmieder, Anne H Caruthers, Shelton D Zhang, Huiying Williams, Todd A Robertson, J. David Wickline, Samuel A Lanza, Gregory M |
description | Our objectives were 1) to characterize angiogenesis in the MDA-MB-435 xenograft mouse model with three-dimensional (3D) MR molecular imaging using α₅β₁(RGD)- or irrelevant RGS-targeted paramagnetic nanoparticles and 2) to use MR molecular imaging to assess the antiangiogenic effectiveness of α₅β₁(ανβ₃)- vs. ανβ₃-targeted fumagillin (50 μg/kg) nanoparticles. Tumor-bearing mice were imaged with MR before and after administration of either α₅β₁(RGD) or irrelevant RGS-paramagnetic nanoparticles. In experiment 2, mice received saline or α₅β₁(ανβ₃)- or ανβ₃-targeted fumagillin nanoparticles on days 7, 11, 15, and 19 posttumor implant. On day 22, MRI was performed using α₅β₁(ανβ₃)-targeted paramagnetic nanoparticles to monitor the antiangiogenic response. 3D reconstructions of α₅β₁(RGD)-signal enhancement revealed a sparse, asymmetrical pattern of angiogenesis along the tumor periphery, which occupied 0.05). Reduction of angiogenesis in MDA-MB-435 tumors from low to negligible levels did not decrease tumor volume. MR molecular imaging may be useful for characterizing tumors with sparse neovasculature that are unlikely to have a reduced growth response to targeted antiangiogenic therapy.--Schmieder, A. H., Caruthers, S. D., Zhang, H., Williams, T. A., Robertson, J. D., Wickline, S. A., Lanza, G. M. Three-dimensional MR mapping of angiogenesis with α₅β₁(ανβ₃)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model. |
doi_str_mv | 10.1096/fj.08-112060 |
format | Article |
fullrecord | <record><control><sourceid>wiley_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2614609</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>FSB2FJ08112060</sourcerecordid><originalsourceid>FETCH-LOGICAL-f2510-310d71b2ddf73f55a6668aa7f4fe210a977254f2500001f0597fbeca6c134993</originalsourceid><addsrcrecordid>eNpVUcFu1DAUtBCIbgs37vgIB5dnO3GcC1JbuhTUFRJdzpZ3Y2e9SuzITik9UsQP9E_ae39hP6JfQqIgJC7vzdO8GWk0CL2icEihFO_s9hAkoZSBgCdoRnMOREgBT9EMZMmIEFzuof2UtgBAgYrnaI9KURaSyxm6XW6iMaRyrfHJBa8bvPiKW911ztc4WKx97UJtvEku4SvXb_Du7vHm9-7-8ebnm93d7mFEv96SXsfa9KbC_cZE7UPq3Rr7AXQ6DrAxCTs_knjx4YgsjknGc_zD-FBHbXvchstkhlmZ5gV6ZnWTzMu_-wAt56fLkzNy_uXjp5Ojc2JZToFwClVBV6yqbMFtnmshhNS6sJk1jIIui4Ll2fALY24LeVnYlVlrsaY8K0t-gN5Ptt3lqjXV2vg-6kZ10bU6Xqugnfqf8W6j6vBdMUEzAaOBnAyuXGOu_wkpqLEXZbcKpJp6UfOLYzb_DHI6B-nrSWp1ULqOLqlvFwwoB5qLgrOC_wHObpPk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Three-dimensional MR mapping of angiogenesis with α₅β₁(ανβ₃)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model</title><source>Wiley Online Library Journals Frontfile Complete</source><source>Alma/SFX Local Collection</source><creator>Schmieder, Anne H ; Caruthers, Shelton D ; Zhang, Huiying ; Williams, Todd A ; Robertson, J. David ; Wickline, Samuel A ; Lanza, Gregory M</creator><creatorcontrib>Schmieder, Anne H ; Caruthers, Shelton D ; Zhang, Huiying ; Williams, Todd A ; Robertson, J. David ; Wickline, Samuel A ; Lanza, Gregory M</creatorcontrib><description>Our objectives were 1) to characterize angiogenesis in the MDA-MB-435 xenograft mouse model with three-dimensional (3D) MR molecular imaging using α₅β₁(RGD)- or irrelevant RGS-targeted paramagnetic nanoparticles and 2) to use MR molecular imaging to assess the antiangiogenic effectiveness of α₅β₁(ανβ₃)- vs. ανβ₃-targeted fumagillin (50 μg/kg) nanoparticles. Tumor-bearing mice were imaged with MR before and after administration of either α₅β₁(RGD) or irrelevant RGS-paramagnetic nanoparticles. In experiment 2, mice received saline or α₅β₁(ανβ₃)- or ανβ₃-targeted fumagillin nanoparticles on days 7, 11, 15, and 19 posttumor implant. On day 22, MRI was performed using α₅β₁(ανβ₃)-targeted paramagnetic nanoparticles to monitor the antiangiogenic response. 3D reconstructions of α₅β₁(RGD)-signal enhancement revealed a sparse, asymmetrical pattern of angiogenesis along the tumor periphery, which occupied <2.0% tumor surface area. α₅β₁-targeted rhodamine nanoparticles colocalized with FITC-lectin corroborated the peripheral neovascular signal. α₅β₁(ανβ₃)-fumagillin nanoparticles decreased neovasculature to negligible levels relative to control; ανβ₃-targeted fumagillin nanoparticles were less effective (P>0.05). Reduction of angiogenesis in MDA-MB-435 tumors from low to negligible levels did not decrease tumor volume. MR molecular imaging may be useful for characterizing tumors with sparse neovasculature that are unlikely to have a reduced growth response to targeted antiangiogenic therapy.--Schmieder, A. H., Caruthers, S. D., Zhang, H., Williams, T. A., Robertson, J. D., Wickline, S. A., Lanza, G. M. Three-dimensional MR mapping of angiogenesis with α₅β₁(ανβ₃)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model.</description><identifier>ISSN: 0892-6638</identifier><identifier>EISSN: 1530-6860</identifier><identifier>DOI: 10.1096/fj.08-112060</identifier><identifier>PMID: 18697838</identifier><language>eng</language><publisher>The Federation of American Societies for Experimental Biology</publisher><subject>antiangiogenic ; cancer ; fumagillin ; magnetic resonance imaging ; molecular imaging ; Research Communications</subject><ispartof>The FASEB journal, 2008-12, Vol.22 (12), p.4179-4189</ispartof><rights>FASEB</rights><rights>2008 FASEB 2008</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1096%2Ffj.08-112060$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1096%2Ffj.08-112060$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids></links><search><creatorcontrib>Schmieder, Anne H</creatorcontrib><creatorcontrib>Caruthers, Shelton D</creatorcontrib><creatorcontrib>Zhang, Huiying</creatorcontrib><creatorcontrib>Williams, Todd A</creatorcontrib><creatorcontrib>Robertson, J. David</creatorcontrib><creatorcontrib>Wickline, Samuel A</creatorcontrib><creatorcontrib>Lanza, Gregory M</creatorcontrib><title>Three-dimensional MR mapping of angiogenesis with α₅β₁(ανβ₃)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model</title><title>The FASEB journal</title><description>Our objectives were 1) to characterize angiogenesis in the MDA-MB-435 xenograft mouse model with three-dimensional (3D) MR molecular imaging using α₅β₁(RGD)- or irrelevant RGS-targeted paramagnetic nanoparticles and 2) to use MR molecular imaging to assess the antiangiogenic effectiveness of α₅β₁(ανβ₃)- vs. ανβ₃-targeted fumagillin (50 μg/kg) nanoparticles. Tumor-bearing mice were imaged with MR before and after administration of either α₅β₁(RGD) or irrelevant RGS-paramagnetic nanoparticles. In experiment 2, mice received saline or α₅β₁(ανβ₃)- or ανβ₃-targeted fumagillin nanoparticles on days 7, 11, 15, and 19 posttumor implant. On day 22, MRI was performed using α₅β₁(ανβ₃)-targeted paramagnetic nanoparticles to monitor the antiangiogenic response. 3D reconstructions of α₅β₁(RGD)-signal enhancement revealed a sparse, asymmetrical pattern of angiogenesis along the tumor periphery, which occupied <2.0% tumor surface area. α₅β₁-targeted rhodamine nanoparticles colocalized with FITC-lectin corroborated the peripheral neovascular signal. α₅β₁(ανβ₃)-fumagillin nanoparticles decreased neovasculature to negligible levels relative to control; ανβ₃-targeted fumagillin nanoparticles were less effective (P>0.05). Reduction of angiogenesis in MDA-MB-435 tumors from low to negligible levels did not decrease tumor volume. MR molecular imaging may be useful for characterizing tumors with sparse neovasculature that are unlikely to have a reduced growth response to targeted antiangiogenic therapy.--Schmieder, A. H., Caruthers, S. D., Zhang, H., Williams, T. A., Robertson, J. D., Wickline, S. A., Lanza, G. M. Three-dimensional MR mapping of angiogenesis with α₅β₁(ανβ₃)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model.</description><subject>antiangiogenic</subject><subject>cancer</subject><subject>fumagillin</subject><subject>magnetic resonance imaging</subject><subject>molecular imaging</subject><subject>Research Communications</subject><issn>0892-6638</issn><issn>1530-6860</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNpVUcFu1DAUtBCIbgs37vgIB5dnO3GcC1JbuhTUFRJdzpZ3Y2e9SuzITik9UsQP9E_ae39hP6JfQqIgJC7vzdO8GWk0CL2icEihFO_s9hAkoZSBgCdoRnMOREgBT9EMZMmIEFzuof2UtgBAgYrnaI9KURaSyxm6XW6iMaRyrfHJBa8bvPiKW911ztc4WKx97UJtvEku4SvXb_Du7vHm9-7-8ebnm93d7mFEv96SXsfa9KbC_cZE7UPq3Rr7AXQ6DrAxCTs_knjx4YgsjknGc_zD-FBHbXvchstkhlmZ5gV6ZnWTzMu_-wAt56fLkzNy_uXjp5Ojc2JZToFwClVBV6yqbMFtnmshhNS6sJk1jIIui4Ll2fALY24LeVnYlVlrsaY8K0t-gN5Ptt3lqjXV2vg-6kZ10bU6Xqugnfqf8W6j6vBdMUEzAaOBnAyuXGOu_wkpqLEXZbcKpJp6UfOLYzb_DHI6B-nrSWp1ULqOLqlvFwwoB5qLgrOC_wHObpPk</recordid><startdate>200812</startdate><enddate>200812</enddate><creator>Schmieder, Anne H</creator><creator>Caruthers, Shelton D</creator><creator>Zhang, Huiying</creator><creator>Williams, Todd A</creator><creator>Robertson, J. David</creator><creator>Wickline, Samuel A</creator><creator>Lanza, Gregory M</creator><general>The Federation of American Societies for Experimental Biology</general><general>Federation of American Societies for Experimental Biology</general><scope>FBQ</scope><scope>5PM</scope></search><sort><creationdate>200812</creationdate><title>Three-dimensional MR mapping of angiogenesis with α₅β₁(ανβ₃)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model</title><author>Schmieder, Anne H ; Caruthers, Shelton D ; Zhang, Huiying ; Williams, Todd A ; Robertson, J. David ; Wickline, Samuel A ; Lanza, Gregory M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-f2510-310d71b2ddf73f55a6668aa7f4fe210a977254f2500001f0597fbeca6c134993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>antiangiogenic</topic><topic>cancer</topic><topic>fumagillin</topic><topic>magnetic resonance imaging</topic><topic>molecular imaging</topic><topic>Research Communications</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schmieder, Anne H</creatorcontrib><creatorcontrib>Caruthers, Shelton D</creatorcontrib><creatorcontrib>Zhang, Huiying</creatorcontrib><creatorcontrib>Williams, Todd A</creatorcontrib><creatorcontrib>Robertson, J. David</creatorcontrib><creatorcontrib>Wickline, Samuel A</creatorcontrib><creatorcontrib>Lanza, Gregory M</creatorcontrib><collection>AGRIS</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The FASEB journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schmieder, Anne H</au><au>Caruthers, Shelton D</au><au>Zhang, Huiying</au><au>Williams, Todd A</au><au>Robertson, J. David</au><au>Wickline, Samuel A</au><au>Lanza, Gregory M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Three-dimensional MR mapping of angiogenesis with α₅β₁(ανβ₃)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model</atitle><jtitle>The FASEB journal</jtitle><date>2008-12</date><risdate>2008</risdate><volume>22</volume><issue>12</issue><spage>4179</spage><epage>4189</epage><pages>4179-4189</pages><issn>0892-6638</issn><eissn>1530-6860</eissn><abstract>Our objectives were 1) to characterize angiogenesis in the MDA-MB-435 xenograft mouse model with three-dimensional (3D) MR molecular imaging using α₅β₁(RGD)- or irrelevant RGS-targeted paramagnetic nanoparticles and 2) to use MR molecular imaging to assess the antiangiogenic effectiveness of α₅β₁(ανβ₃)- vs. ανβ₃-targeted fumagillin (50 μg/kg) nanoparticles. Tumor-bearing mice were imaged with MR before and after administration of either α₅β₁(RGD) or irrelevant RGS-paramagnetic nanoparticles. In experiment 2, mice received saline or α₅β₁(ανβ₃)- or ανβ₃-targeted fumagillin nanoparticles on days 7, 11, 15, and 19 posttumor implant. On day 22, MRI was performed using α₅β₁(ανβ₃)-targeted paramagnetic nanoparticles to monitor the antiangiogenic response. 3D reconstructions of α₅β₁(RGD)-signal enhancement revealed a sparse, asymmetrical pattern of angiogenesis along the tumor periphery, which occupied <2.0% tumor surface area. α₅β₁-targeted rhodamine nanoparticles colocalized with FITC-lectin corroborated the peripheral neovascular signal. α₅β₁(ανβ₃)-fumagillin nanoparticles decreased neovasculature to negligible levels relative to control; ανβ₃-targeted fumagillin nanoparticles were less effective (P>0.05). Reduction of angiogenesis in MDA-MB-435 tumors from low to negligible levels did not decrease tumor volume. MR molecular imaging may be useful for characterizing tumors with sparse neovasculature that are unlikely to have a reduced growth response to targeted antiangiogenic therapy.--Schmieder, A. H., Caruthers, S. D., Zhang, H., Williams, T. A., Robertson, J. D., Wickline, S. A., Lanza, G. M. Three-dimensional MR mapping of angiogenesis with α₅β₁(ανβ₃)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model.</abstract><pub>The Federation of American Societies for Experimental Biology</pub><pmid>18697838</pmid><doi>10.1096/fj.08-112060</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0892-6638 |
ispartof | The FASEB journal, 2008-12, Vol.22 (12), p.4179-4189 |
issn | 0892-6638 1530-6860 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2614609 |
source | Wiley Online Library Journals Frontfile Complete; Alma/SFX Local Collection |
subjects | antiangiogenic cancer fumagillin magnetic resonance imaging molecular imaging Research Communications |
title | Three-dimensional MR mapping of angiogenesis with α₅β₁(ανβ₃)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T13%3A26%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Three-dimensional%20MR%20mapping%20of%20angiogenesis%20with%20%CE%B1%E2%82%85%CE%B2%E2%82%81(%CE%B1%CE%BD%CE%B2%E2%82%83)-targeted%20theranostic%20nanoparticles%20in%20the%20MDA-MB-435%20xenograft%20mouse%20model&rft.jtitle=The%20FASEB%20journal&rft.au=Schmieder,%20Anne%20H&rft.date=2008-12&rft.volume=22&rft.issue=12&rft.spage=4179&rft.epage=4189&rft.pages=4179-4189&rft.issn=0892-6638&rft.eissn=1530-6860&rft_id=info:doi/10.1096/fj.08-112060&rft_dat=%3Cwiley_pubme%3EFSB2FJ08112060%3C/wiley_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/18697838&rfr_iscdi=true |